An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors

Maicol Mancini¹, Hilah Gal², Nadège Gaborit¹, Luigi Mazzeo¹, Donatella Romaniello¹, Tomer Meir Salame³, Moshit Lindzen¹, Georg Mahlknecht¹, Yehoshua Enuka¹, Dominick GA Burton², Lee Roth¹, Ashish Noronha³, Ilaria Marrocco³, Dan Adreka³, Raya Eilam Altstadter⁴, Emilie Bousquet⁵, Julian Downward⁶⁷, Antonio Maraver⁵, Valery Krizhanovsky² and Yosef Yarden¹* ²

Abstract

EGFR mutations identify patients with lung cancer who derive benefit from kinase inhibitors. However, most patients eventually develop resistance, primarily due to the T790M second-site mutation. Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit T790M-EGFR, but several mechanisms, including a third-site mutation, C797S, confer renewed resistance. We previously reported that a triple mixture of monoclonal antibodies, 3×mAbs, simultaneously targeting EGFR, HER2, and HER3, inhibits T790M-expressing tumors. We now report that 3×mAbs, including a triplet containing cetuximab and trastuzumab, inhibits C797S-expressing tumors. Unlike osimertinib, which induces apoptosis, 3×mAbs promotes degradation of the three receptors and induces cellular senescence. Consistent with distinct mechanisms, treatments combining 3×mAbs plus sub-inhibitory doses of osimertinib synergistically and persistently eliminated tumors. Thus, oligoclonal antibodies, either alone or in combination with kinase inhibitors, might preempt repeated cycles of treatment and rapid emergence of resistance.

Keywords antibody therapy; apoptosis; kinase inhibitor; NSCLC; T790M

Introduction

Somatic mutations in the gene encoding the epidermal growth factor receptor (EGFR) are detected in approximately 12% of non-small cell lung cancers (NSCLCs) from Caucasian patients and in 30–40% of NSCLCs from Asian patients (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). All oncogenic mutations locate to the catalytic, tyrosine-specific kinase domain of EGFR. Two aberrations, the L858R mutation and the exon 19 deletion (del746-750), represent the vast majority of activating EGFR mutations. Treatment of patients with gefitinib or erlotinib, two reversible tyrosine kinase inhibitors (TKIs), is associated with response rates that are superior to treatment with chemotherapy (Mok et al., 2009). However, despite initial drug activity, all patients acquire resistance within approximately 1 year (Mok et al., 2009; Rosell et al., 2009). The most common mechanism (> 50%) of acquired resistance involves a secondary mutation, T790M (Kobayashi et al., 2005; Pao et al., 2005; Oxnard et al., 2011).

Two strategies have been developed to overcome EGFR TKI resistance. The first involves synthesis of novel compounds (Zhou et al., 2009), including irreversible TKIs, which covalently conjugate to cysteine 797 of EGFR. For example, afatinib (Gilotrif®) covalently binds with EGFR and HER2 (Regales et al., 2009). However, inhibition of wild-type EGFR and relatively high drug doses required for inhibition of T790M-EGFR (Yap et al., 2010) limit afatinib application. Secondly, a combination of afatinib and cetuximab (an anti-EGFR monoclonal antibody) overcomes T790M-mediated resistance (Regales et al., 2009; Keating, 2014). A study that combined afatinib and cetuximab, and recruited patients who acquired TKI resistance, showed an overall response rate of 29%, but this result was comparable in T790M-positive and in T790M-negative tumors (Janjigian...
The pharmacological limitations of second-generation inhibitors might be overcome by the newest, third-generation inhibitors, such as osimertinib, CO-1666 (rociletinib), and HM61713 (reviewed in Costa & Kobayashi, 2015; Mancini & Yarden, 2015). Osimertinib inhibits T790M-EGFR, while sparing wild-type EGFR (Liao et al, 2015). In a phase I trial, osimertinib demonstrated manageable tolerability and 51% response rate among T790M mutant tumors (Janne et al, 2015). Subsequent studies not only demonstrated that osimertinib has significantly greater efficacy than chemotherapy (Mok et al, 2017), but also confirmed its ability to provide a high overall response rate, as well as confer durable response (Yang et al, 2017). Nevertheless, patients treated with osimertinib acquire resistance, due to several mechanisms, including emergence of C797S mutations (Eberlein et al, 2015; Thress et al, 2015). Other mechanisms include aberrant expression of NRAS and KRAS (Eberlein et al, 2015), or activation of MET and HER2, a kin of EGFR (Planchard et al, 2015).

Unlike the mutation-prone intracellular domain of EGFR, the extracellular domain is rarely mutated, which predicts low incidence of resistance to anti-EGFR monoclonal antibodies (mAbs). We previously examined this strategy and uncovered compensatory loops that increase transcription of HER2 and HER3 in response to an anti-EGFR mAb (Mancini et al, 2015). Preventing this by means of a triple combination of mAbs to EGFR, HER2 and HER3 (hereinafter, 3×mAbs) robustly inhibited tumor growth. The present study compares 3×mAbs and osimertinib. While in animal models, both treatments effectively inhibited growth of T790M-positive tumors, when tested in vitro and in animals osimertinib-induced apoptosis, whereas 3×mAbs caused cellular senescence and weak apoptosis. Importantly, prolonged exposure to osimertinib promoted emergence of resistant tumor cells, including C797S-EGFR expressing cells, which remained sensitive to 3×mAbs. Congruent with distinct mechanisms of action of 3×mAbs and osimertinib, treatments of tumor-bearing mice with 3×mAbs plus a sub-inhibitory dose of osimertinib durably prevented tumor relapses after ending all treatments. Taken together, these observations offer a new NSCLC treatment strategy, potentially able to overcome many, if not all resistance-conferring EGFR kinase mutations.

**Results**

**Combining trastuzumab and cetuximab with an anti-HER3 antibody strongly inhibits erlotinib-resistant tumors**

EGFR’s intracellular part presents mutations responsible for recurring TKI resistance (Camidge et al, 2014), but the ectodomain is rarely mutated, such that anti-EGFR antibodies might overcome mutation-driven resistance to TKIs. We previously examined this scenario using two NSCLC cell lines (Mancini et al, 2015): patient-derived H1975 cells expressing a double mutant of EGFR, L858R, and T790M, and the PC9ER cell line, a derivative of PC9 (del746-750 EGFR), which acquired the T790M mutation (de Bruin et al, 2014). Inhibition of both animal models required simultaneous treatment with three homemade mAbs, to EGFR, HER2, and HER3 (Mancini et al, 2015). Similarly, we now report that combining two clinically approved mAbs, cetuximab (anti-EGFR) and trastuzumab (anti-HER2), with a murine anti-HER3 (mAb33), partly inhibited *in vitro* growth of PC9ER and H1975 cells (Fig EV1A) and almost completely prevented tumorigenic growth of PC9ER cells in animals (Fig 1A). Moreover, this effect persisted at least 30 days post-treatment. In similarity to the murine anti-EGFR antibodies we previously tested (Mancini et al, 2015), cetuximab was more effective *in vivo* than singly applied anti-HER2 or anti-HER3 antibodies. In conclusion, the therapeutic activities of cetuximab and trastuzumab can be augmented by adding an anti-HER3 antibody, such that the oligoclonal mixture of two humanized antibodies and a murine mAb persistently inhibits TKI-resistant NSCLC models.

**Third-generation TKIs and 3×mAbs comparably inhibit TKI-resistant tumors, but their biological effects are distinct**

Toward *in vivo* comparisons of 3×mAbs and a third-generation TKI, we examined effects on metabolic activity and EGFR phosphorylation. As predicted, the third-generation TKIs completely inhibited metabolic activity of PC9, PC9ER, and H1975 cells (Figs 1B and EV1B). In contrast, 3×mAbs achieved only partial (≤50%) inhibition of metabolic activity, even at relatively high concentrations. Unlike erlotinib, which exerted no consistent effect on EGFR phosphorylation, both third-generation inhibitors we tested, osimertinib and CO-1686 (Sequist et al, 2015), strongly reduced EGFR phosphorylation in PC9ER cells, and this was associated with parallel decreases in downstream phosphorylation of AKT and ERK (Fig 1C). Interestingly, 3×mAbs only partly reduced phospho-EGFR signals, an effect attributable to EGFR degradation. Accordingly, the antibodies strongly reduced pERK. However, 3×mAbs spared the basally active AKT. In contrast to the antibodies, the TKIs caused no detectable EGFR degradation, but both inhibitors elevated HER3 (and HER2) surface expression, while 3×mAbs induced down-regulation of surface EGFR, HER2, and HER3 (Fig EV1C), consistent with the reported effect on receptor endocytosis (Mancini et al, 2015). In conclusion, the set of *in vitro* assays uncovered remarkable differences between 3×mAbs and osimertinib: While the former reduced surface expression of the target receptors and inhibited pERK, it only partly inhibited metabolism and did not significantly affect pAKT. In contrast, the irreversible TKI strongly inhibited pEGFR, pAKT, pERK, and cellular metabolism, but it up-regulated surface HER3 and HER2.

Next, we compared the ability of 3×mAbs and osimertinib to inhibit tumor growth in mice. Interestingly, both treatments effectively inhibited tumorigenic growth of H1975 cells, but osimertinib achieved an earlier effect (Fig 1D). As expected, both osimertinib and 3×mAbs strongly reduced expression of Ki67, a proliferation antigen (Figs 1E and EV1D). The inhibitory effects were reflected also by another test, which administered the two drugs to animals already bearing relatively large H1975 tumors (Fig 1F and G). Immunohistochemical analyses of excised tumors confirmed, on the one hand, the ability of osimertinib to strongly inhibit EGFR phosphorylation and, on the other hand, the ability of 3×mAbs to downregulate EGFR abundance in tumors (Fig EV1E). To address potential toxicities, we analyzed body weights. While animals treated with 3×mAbs gained weight in the course of the experiment (45 days), mice treated with osimertinib displayed slower rates of weight gain (Fig EV1F). In
Figure 1. Both third-generation TKIs and a triple mAb mixture inhibit erlotinib-resistant tumors, but their mechanisms of action might differ.

A PC9ER cells (4 × 10^6 cells per animal) were subcutaneously implanted in CD1-nu/nu mice. Thereafter, tumor-bearing mice were randomized into groups of 9–10 animals that were later treated with the indicated antibodies (0.2 mg/mouse/injection) once every 3 days, for 30 days. Thereafter, tumor growth was followed without any further treatment. Data are means ± SEM from nine mice in each group. CTX, cetuximab; TRZ, trastuzumab; mAb 33, a monoclonal anti-human HER3 antibody; PBS, saline control.

B Metabolic activity of PC9ER and H1975 cells cultured for 4 days in the presence of increasing concentrations of erlotinib, osimertinib, CO-1686 (rociletinib), or the triple antibody combination (CTX, TRZ, and mAb 33). Data are means ± SD values from three experiments.

C PC9ER cells were treated overnight with the indicated TKIs, or with 3XmAbs, and whole-cell extracts were prepared. Cleared extracts were electrophoresed, and resolved proteins were transferred onto filters. Filters were immunoblotted for the indicated proteins or for their phosphorylated forms. Blots are representative of two independent experiments.

D H1975 NSCLC cells (3 × 10^6 cells per animal) were subcutaneously grafted in the flanks of CD1-nu/nu mice. Animals were randomized into groups of eight mice after tumors became palpable. Erlotinib (50 mg/kg/dose) and osimertinib (5 mg/kg/dose) were daily administered using oral gavage, whereas the triple antibody combination (3XmAbs; CTX, TRZ, and mAb 33; 0.2 mg/mouse/injection) and saline (vehicle) were administered intraperitoneally once every 3 days. Data are means ± SEM values. The broken horizontal line marks the initial tumor volume.

E H1975 NSCLC cells (3 × 10^6 cells per animal) were subcutaneously grafted in the flanks of four groups of CD1-nu/nu mice. Animals were subjected to the following treatments: erlotinib (50 mg/kg/dose daily treatment), osimertinib (5 mg/kg/daily treatment), or 3XmAbs (CTX, TRZ and mAb 33; 0.2 mg/mouse/injection) administered twice a week. Immunohistochemical staining for Ki67 in paraffin-embedded sections was performed (see Fig EV1D), and the results are presented in box and whisker plots, where the ends of the box are the upper and lower quartiles, the median is marked by a line inside the box and the whiskers mark the highest and lowest values. Depicting quantifications of Ki67 staining using 6–8 sections/tumor. Statistical calculations refer to the control group as reference. ***P < 0.001, ****P < 0.0001; n = 5; one-way ANOVA with Tukey’s test.

F, G H1975 NSCLC cells (3 × 10^6 cells per animal) were subcutaneously grafted in the flanks of three groups of CD1-nu/nu mice. Animals were subjected to erlotinib treatment (50 mg/kg/dose), which continued until tumors reached 800 mm^3. Thereafter, each group received one of the following treatments: erlotinib (50 mg/kg/dose), osimertinib (5 mg/kg/dose) or 3XmAbs (CTX, TRZ and mAb 33; 0.2 mg/mouse/injection) administered as in (D). Data are means ± SEM from seven mice in each group. Also shown are tumors harvested from each group of animals. Scale bar, 1 cm.

Source data are available online for this figure.
addition, only small differences in favor of fat accumulation in antibody-treated animals were observed when using fat/lean analyses (Fig EV1G). In summary, treatments using osimertinib and 3×mAbs are comparably effective and safe when tested in mice, but the TKI achieves faster kinetics, probably due to complete inhibition of the AKT survival pathway.

Third-generation TKIs strongly induce apoptosis of erlotinib-resistant cells

In line with a TKI-specific effect on cell growth and survival, we observed a decrease in S-phase cells and a parallel increase in the fraction of cells found in the G0/G1 phase of the cell cycle (Fig 2A).
sis, osimertinib increased both early and late apoptosis, and supported our conclusion that osimertinib induces stronger cell death than the anti-bodies (Figs EV2B and 2C). To help distinguish between early and late apoptosis, we used 7-amino-actinomycin D (7-AAD). Early apoptotic cells exclude 7-AAD, while late-stage apoptotic cells stain positively, due to passage of the dye into the nucleus. Interestingly, whereas a cytotoxic agent, cisplatin, increased primarily late apoptosis, osimertinib increased both early and late apoptosis, and combining cisplatin and 3-mAbs increased late apoptosis (Fig 2C), in line with a recent study (Ellebaek et al., 2016). Consistent with the in vitro observations, widespread caspase-3 cleavage was observed in H1975 and in PC9ER xenografts already 4 days after osimertinib treatment (Fig 2D and E). In summary, the third-genera-tory TKI, more than 3-mAbs, induces apoptosis of erlotinib-resistant cells both in vitro and in animals.

The triple antibody combination induces growth arrest and senescence of TKI-resistant NSCLC cells

Because of the relatively weak apoptosis observed following treatment with 3-mAbs, we considered alternative growth inhibitory mechanisms. Prolonged exposure of PC9ER cells to 3-mAbs induced marked alterations, such as an enlarged and flat morphology (Fig 3A), which might herald cellular senescence (Campisi, 2012; Burton & Krizhanovsky, 2014; Salama et al., 2014). Indeed, treatment of cultured PC9 and H1975 cells with 3-mAbs induced prominent activity of SA-β-Gal (senescence-associated β-galactosidase; Figs 3B and EV3A), a hallmark of
cellular senescence (Dimri et al., 1995). Elevation of additional senescence markers was noted in vitro, such as DCR2 (TNFRSF10D) and several inhibitors of cyclin-dependent kinases, namely p16, p21, and p27/KIP (Figs 3C and EV3B). Importantly, analyses of an erlotinib-resistant animal model confirmed that 3×mAbs, more than osimertinib, elevated SA-β-Gal activity.
In view of the remarkably different mechanisms of action of oligoclonal antibodies and osimertinib, we assumed that their combination might elicit strong and durable anti-tumor effects. To examine this prediction in an animal model, we adopted a three-step scenario: First, PC9ER cells were implanted in the flanks of CD1-nu/nu mice that were later subjected to erlotinib treatment. On day 20, tumor-bearing mice were randomized into the following arms: (1) vehicle control, (2) erlotinib, (3 and 4) high and low doses of osimertinib, (5) the triple antibody combination (3 mAbs), and (6 and 7) two different combinations of 3 mAbs and osimertinib. These studies confirmed the inhibitory effect of 3 mAbs and the more rapidly evolving effect of osimertinib (Fig 4A and B). Moreover, combining a weakly active dose of osimertinib with 3 mAbs synergistically inhibited tumorigenic growth, while inducing no overt toxicity (Fig EV4A and B). Notably, the combination of 3 mAbs and a TKI achieved complete tumor inhibition, and no relapses were observed in this arm long after treatment termination (> 40 days). In contrast, once osimertinib monotherapy was stopped, tumors rapidly relapsed, but only in one of the nine mice treated with 3 mAbs monotherapy did tumors re-appear, and no relapses were observed when 3 mAbs was co-administered with low- or high-dose oral osimertinib (Figs 4A and B, and EV4C). Immunostaining of the corresponding xenografts for Kl67 confirmed that the combination of low-dose osimertinib and 3 mAbs arrested cell proliferation more effectively than each drug alone (Fig 4C and D). In summary, the observations we made in tumor-bearing animals identified an especially effective combination of antibodies and osimertinib that exerts persistent tumor-inhibitory effects, which might reflect the remarkably different mechanisms of action of oligoclonal antibodies and irreversible TKIs.

Enhancement of receptor endocytosis, as well as more robust apoptosis, may explain the cooperative anti-tumor actions of 3 mAbs and osimertinib

Gratifyingly, we detected the resistance-conferring C797S mutation (Thress et al, 2015) in one of six mice that rapidly relapsed post-treatment with high-dose osimertinib (Fig 4E). This observation, together with the augmented anti-proliferation effect of the antibody–TKI combination (Fig 4D), prompted us to investigate mechanism(s) underlying inhibition of relapse of mutation-bearing and possibly other resistant clones. We previously attributed the anti-tumor effects of 3 mAbs to simultaneous endocytosis and degradation of the three target receptors for EGFR-like growth factors (Mancini et al, 2015). In line with this interpretation, the combination of two drugs more effectively destabilized HER3, HER2, and EGFR in PC9ER cells (Fig 5A). Furthermore, using cytometry, this effect was linked to removal of the three receptors from the cell surface (Fig 5B). Interestingly, we noted that in vitro treatment with osimertinib augmented surface expression, along with overall abundance of HER3 and HER2 (Fig 5B), suggesting that TKI monotherapy might enhance recognition of mutant-expressing cells by 3 mAbs.

To examine in vivo relevance of antibody-induced endocytosis and degradation, we treated mice harboring H1975 xenografts for 10 days. Thereafter, tumors were harvested and fixed and thin slices were analyzed by immunofluorescence using anti-EGFR, anti-HER2, and anti-HER3 antibodies (Fig 5C). As expected, we observed bright staining with all three antibodies when untreated, or when erlotinib-treated tumors were examined. Treatment with osimertinib
Figure 4. Unlike the kinase inhibitor, the oligoclonal antibody prevents post-treatment relapses, especially when combined with low-dose osimertinib.

A PC9ER cells ($3 \times 10^6$ cells per animal) were implanted in the flanks of CD1-nu/nu mice. Once palpable tumors emerged, mice were daily treated with erlotinib (50 mg/kg/dose; 1st step). Following randomization of mice, we started the following arms of second step treatment: (1) vehicle control, (2) erlotinib, (3 and 4) osimertinib (1 or 5 mg/kg/dose; L or H, respectively), (5) the triple antibody combination, which was injected intraperitoneally once every 3 days, (6 and 7) and combinations of 3×mAbs (0.2 mg/mouse/dose) and osimertinib, either high or low. All treatments were stopped on day 50, but we continued monitoring tumor volumes (post-treatment phase). Data are means ± SEM from 9 to 10 mice of each group.

B Kaplan–Meier survival analysis of the tumor-bearing mice shown in (A). Mice were euthanized when tumor volumes reached 1,500 mm$^3$.

C, D One week after inoculation of PC9ER cells, mice were randomized (4 mice/group) and treated for 14 days as described in (A) (arms 1, 4, 5, and 7). Shown is immunohistochemical staining for KI67 in paraffin-embedded sections using specific antibodies. Scale bars, 100 μm. Also shown are box and whisker plots (note that the ends of the box are the upper and lower quartiles and the median is marked by a line inside the box) depicting quantifications of KI67 staining. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n = 6, one-way ANOVA with Tukey’s test.

E Genomic DNA, along with the indicated plasmid DNA reference samples, were tested for EGFR’s T790M and C797S mutations using the TaqMan genotyping assay DNA was isolated from six relapsing tumors, all from mice treated with osimertinib (high dose; arm 4 in panel A). Fluorescent signals corresponding to individual tumors and mice are shown as small colored dots, whereas large dots represent signals obtained from plasmid DNA. Note that VIC-labeled primers were used for amplification of wild-type alleles, whereas FAM-labeled primers were used for the mutant alleles. As indicated, only one animal, mouse number 5 (#5), scored positive for a mutant C797S allele. Data were analyzed using TaqMan Genotyper Software (Life technologies). NTC, no-template control.
Figure 5. Enhancement of receptor endocytosis, as well as cellular apoptosis, may explain the cooperative anti-tumor actions of 3XmAbs and osimertinib.

A. PC9ER cells were treated for 24 h with DMSO (control) or osimertinib (10 nM or 100 nM), in the absence or presence of 3XmAbs (30 μg/ml). Whole-cell extracts were analyzed using electrophoresis and immunoblotting. Blots are representative of three independent experiments.

B. PC9ER cells were treated for 24 h with saline (CTRL), 3XmAbs (40 μg/ml), osimertinib (500 nM), or with the combination (3XmAbs plus osimertinib). Thereafter, cells were analyzed using flow cytometry for surface expression levels of EGFR, HER2, and HER3. Normalized surface expression levels are presented as means ± SEM of two independent experiments.

C. CD1-nu/nu mice harboring H1975 xenografts were treated for 10 days, as indicated. Thereafter, tumors were harvested, formalin-fixed, and paraffin-embedded (FFPE). The corresponding sections (4 μm), obtained from each tissue block were analyzed by immunofluorescence using anti-EGFR, anti-HER2, and anti-HER3 antibodies. Afterward, sections were washed and incubated for 90 min at room temperature with a biotinylated anti-rabbit secondary antibody, followed by Cy3-conjugated streptavidin. Sections were washed and covered with Aqua Polymount. Stained sections were examined and photographed using a fluorescence microscope (Eclipse NI-U, Nikon, Tokyo, Japan) equipped with a Plan Fluor objectives (Nikon). Scale bar, 25 μm. Also shown are histograms depicting quantifications of receptor staining (mean = SD). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n = 3, one-way ANOVA with Tukey’s test.

D. PC9ER cells were treated for the indicated time intervals with osimertinib (500 nM), 3XmAbs (20 μg/ml), or the combination of both treatments. Whole-cell extracts were analyzed for caspase-9 and cleavage products. GAPDH levels were used for comparison of gel loading.

E. Mice bearing PC9ER tumor xenografts were treated for 7 days with either vehicle, 3XmAbs (0.2 mg/mouse/dose), osimertinib high (H, 5 mg/kg/dose), or low (L, 1 mg/kg/dose), or with the indicated combinations. Tumor extracts were probed for caspase-3 and the cleaved form. Tubulin was used to compare the amounts of protein loaded.

Source data are available online for this figure.
was associated with the appearance of some necrotic foci, along with moderate effects on receptor levels. As predicted by our in vitro assays, significantly stronger negative effects on the abundance of the three receptors were observed when tumors were pre-treated with 3×mAbs, either alone or in combination with osimertinib.

To address apoptosis, we utilized three different molecular markers and inferred enhancement of TKI-induced apoptosis by 3×mAbs. Thus, 3×mAbs instigated weak cleavage of PARP (poly(ADP-ribose) polymerase), a maker of apoptosis, but the signals observed after treatment with the drug combination (especially low doses of osimertinib) exceeded those induced by each agent alone (Fig EV4D). Likewise, augmented osimertinib-induced cleavage of caspase-3 was observed following a prolonged in vitro treatment (11 days) of PC9ER cells with 3×mAbs, although when applied alone the antibodies induced no cleavage (Fig EV4E). Consistent with caspase-3 activation, analysis of an upstream protease, caspase-9, confirmed that the combination of drugs enhanced appearance of the p17 cleaved form (Fig 5D). In a similar manner, although osimertinib alone induced activation of BIM and 3×mAbs was weakly effective, enhanced BIM activation was observed following treatment with the combination (Fig EV4F). For in vitro relevance, we treated mice bearing PC9ER xenografts with osimertinib, 3×mAbs, or the combinations and observed, 7 days later, a clear enhancement of caspase-3 cleavage (Fig 5E), similar to the results obtained using cultured cells.

Next, we addressed the prediction that antibody-induced enhancement of apoptosis translates to stronger inhibition of cell proliferation. For example, 3×mAbs induced only a small effect on the S-phase fraction of PC9ER cells, but cell division almost stopped when the antibodies were combined with osimertinib (Fig EV4G), which might explain the synergistic action of the antibody plus TKI combination. Taken together, the cooperative effects of the combination of osimertinib and three antibodies, in terms of both endocytosis and apoptosis, are consistent with the pharmacological prediction of collaboration between two drugs employing distinct modes of action.

Cells that acquire the C797S mutation, which confers resistance to osimertinib, remain sensitive to the triple antibody combination

Because spontaneous emergence of the C797S mutation was observed in an animal model, as shown in Fig 4E, we were prompted to establish a parallel in vitro system of acquired resistance. To this end, we incubated PC9ER cells for 4 months with osimertinib and isolated surviving cells (hereinafter, PC9ER-AZDR cells). As expected, the IC50 value of PC9ER-AZDR cells toward the inhibitor increased by 2–3 orders of magnitude, relative to the parental cells (Figs 6A and EV5A), the drug lost the ability to inhibit phosphorylation of EGFR, AKT, and ERK (Fig 6B), and initial genotyping proposed emergence of the C797S mutation (Fig EV5B).

Interestingly, PC9ER-AZDR cells also acquired resistance to CO-1686, another third-generation TKI. One potentially shared mechanism of resistance might involve elevated EGFR abundance, as revealed by immunoblot and real-time PCR analyses (Figs 6B and C, and EV5C). Because PC9ER-AZDR cells also acquired resistance to afatinib (Fig EV5A), an irreversible TKI that depends on an intact cysteine at position 797, we analyzed in greater depth the emergence of the previously reported C797S mutation (Thress et al., 2015). Indeed, by applying a digital PCR-based assay on genomic DNA extracted from PC9ER-AZDR cells, we confirmed the presence of the C797S mutation (Fig EV5B–D; see Appendix Table S1). It is notable that we mapped the two resistance-promoting mutations, namely T790M and C797S, to the same allele, a configuration preempting combined treatment with first- and third-generation EGFR inhibitors. Moreover, determination of copy number variation using digital PCR and the Fluidigm Biomark platform indicated that acquisition of osimertinib resistance involved amplification of the del746/750 allele, along with selective enrichment for the...
T790M-containing allele and *de novo* emergence of the C797S allele (Figs 6D, and FVE5E and F, and Appendix Table S2).

To address in animals the ability of 3×mAbs to overcome resistance to osimertinib, we inoculated PC9ER-AZDR cells in CD1-nu/nu mice, which were later treated with either osimertinib or antibodies. As expected, neither erlotinib nor osimertinib inhibited growth of the corresponding tumors in animals (Fig 6E). On the contrary, treatment with 3×mAbs strongly and persistently reduced tumor volumes, and no relapses were observed >90 days after ending all antibody treatments. Immunohistochemical staining of xenografts confirmed the ability of 3×mAbs, unlike osimertinib, to arrest cell proliferation (Fig 6F), as well as increase cellular senescence, as revealed by β-galactosidase activity (Fig 6G), in line with a senescence-associated mechanism of tumor inhibition.

Figure 6.
In conclusion, NSCLC cells that acquired resistance to first-, second-, and third-generation TKIs remain sensitive to an antibody combination able to simultaneously down-regulate EGFR, HER2, and HER3. Hence, it is conceivable that 3×mAbs would be able to nullify, in clinical settings, TKI resistance driven by the C797S mutation. Our future studies will address, on the one hand, the ability of 3×mAbs to overcome other mechanisms of resistance to irreversible TKIs and, on the other hand, mechanisms of putative resistance to 3×mAbs, possibly due to activation of alternative driver oncogenes (e.g., MET amplification) or to emergence of downstream mutations (e.g., in NRAS) (Eberlein et al., 2015).

Discussion

Osimertinib is the first clinically approved drug that specifically targets T790M-mutated EGFRs (Janne et al., 2015), but several mechanisms, including emergence of the C797S mutation, will likely limit durability of responses to the new, third-generation inhibitors (Eberlein et al., 2015; Thress et al., 2015). The rationale behind developing 3×mAbs as a potential alternative strategy is dual: (i) the combination of three antibodies nullifies compensatory feedback loops involving HER2 and HER3 (Mancini et al., 2015), and (ii) 3×mAbs recognizes the genetically more stable parts of EGFR, HER2, and HER3, namely the extracellular domains, independently of the identity and number of intracellular mutations. Our animal studies, although confined to only two model cell lines, indicate that all three mAbs must be co-administered in order to fully eliminate pre-established NSCLC tumors. Although this therapeutic effect develops slowly, in comparison with the rapid effect of osimertinib, in our models only rarely did recurrence slowly follow completion of 3×mAbs treatment. This is in marked contrast to osimertinib: Soon after complete regression and treatment cessation, tumors rapidly regrew. Notably, according to a recent study, relapses may be due to a variety of mechanisms, including pre-existing mutants of EGFR and newly generated mutations (Hata et al., 2016; Ramirez et al., 2016). Because only one of six animals relapsing after osimertinib treatment tested positive for the C797S mutation, and a parallel experimental arm showed strong inhibition of relapses by 3×mAbs, we assume that 3×mAbs also blocks alternative modes of resistance to osimertinib. Altogether, our data indicate that 3×mAbs is active against the following mutations: L858R, del746-750, T790M, and C797S. This list predicts that yet unknown kinase domain mutations will show similar sensitivities. Nevertheless, co-administration of three different mAbs is expected to cause some adverse effects, such as skin and gastrointestinal tract toxicities (Kol et al., 2014; Gaborit et al., 2015).

Several mechanisms may underlay the ability of mAbs to inhibit tumor growth. They include recruitment of immune effector cells, complement-dependent cytotoxicity, interception of pathways essential for tumorigenesis, induction of apoptosis, and stimulation of receptor degradation (Carvalho et al., 2016). However, so far the contribution of cellular senescence has not been addressed. It is notable that cells undergoing senescence not only arrest their own proliferation; by secreting cytokines, they recruit and activate immune cells, including macrophages and NK cells (Munoz-Espin & Serrano, 2014). Furthermore, while undergoing senescence, cells can up-regulate immune ligands on their own surface, thereby engage mechanisms capable of eliminating senescent cells (Sagiv & Krizhanovsky, 2013). Because our immunocompromised animal model precludes in-depth analysis of immune mechanisms leading to tumor shrinkage, we focused on non-immune processes, such as cellular senescence and antibody-mediated endocytosis and degradation of receptors for survival factors.

It is notable that our animal studies uncovered cooperative interactions between 3×mAbs and low-dose osimertinib: following a relatively short treatment (4 weeks), all treated mice were cured by the mAb-TKI combination. We attribute synergy to, on the one hand, the ability of 3×mAbs to sort survival receptors for degradation, thereby instigate senescence, and, on the other hand, to the ability of osimertinib to strongly induce apoptosis. In other words, the mAb-TKI combination harnesses two different inhibitory mechanisms, which might augment each other. Although we did not address immunological mechanisms, it is worthwhile indicating that trastuzumab can mediate ADC in animals (Clynes et al., 2000) and polymorphic isoforms of Fcγ receptors, which mediate ADC, have been implicated in responses of colorectal and breast cancer patients to cetuximab (Zhang et al., 2007; Bibeau et al., 2009) and trastuzumab (Musolino et al., 2008), respectively. Along a similar vein, complement-mediated anti-tumor activity of trastuzumab has been demonstrated (Mamidi et al., 2013). Examination of such in vivo actions of 3×mAbs is currently limited by the availability of suitable animal models.

In summary, our studies identify a combination of three antibodies, two of them are clinically approved for other diseases, as a potent treatment able to persistently inhibit models of EGFR-driven NSCLC. The data imply that the triple antibody mixture will block all kinase domain mutants of EGFR, hence avoid repeated cycles of resistance due to emergence of new mutations. Furthermore, combining the oligoclonal antibody with a low dose of a third-generation inhibitor of EGFR improved anti-tumor efficacy, avoided recurrence, and durably cleared tumors in mice, features that may justify larger scale tests of 3×mAbs, either alone or in combinations, in clinical settings.

Materials and Methods

Real-time and digital PCR (dPCR)

Total RNA was isolated using PerfectPure RNA Cultured Cell Kit (5′-prime, Hamburg). Complementary DNA was synthesized using the miScript kit (QIAGEN). Primers were designed using Primer3. Real-time qPCR analyses were performed using SYBR Green (QiaGen or Applied Biosystems) and specific primers (see a list of primers in Appendix Table S3). qPCR signals (cT) were normalized to B2M.

Digital PCR experiments were performed using the Fluidigm Biomark platform in 12,765 chip format. The primers we used are listed in Appendix Table S4. All dPCR reagents and assays were from Life Technologies. Genomic DNA was isolated from cell lines using Pure Link Genomic DNA mini kit. Stocks (10 ng/μl) of each DNA sample were serially diluted (1:1, 1:2, 1:4, 1:8, 1:16). For reference, we used two control plasmid DNAs (1 pg): pCDNA3-EGFRwt and pCDNA3-EGFRdel746/50 + T790M + C797S. For primer sequences, see a list in Appendix Table S3. RNase P, copy number reference assay, and all of the other SNP reagents were obtained.
from Applied Biosystems. Cycling conditions were as follows: 60°C for 30 s (1 cycle), 95°C for 10 min (1 cycle), 40 cycles of 94°C for 15 s and 60°C for 1 min, followed by 10°C hold. The count of partitions showing positive amplification was obtained using Fluidigm Digital PCR Analysis software. This count was analyzed after Poisson correction, to account for the fact that some positive partitions might contain more than one DNA molecule. As the number of positive partitions increases, so does the probability that some partitions will contain more than one target molecule (Sanders et al., 2013). The corrected values were provided by the Fluidigm software as “Estimated Targets”. To calculate the number of copies per ng of genomic DNA, we used the following equation: no. of copy/ngDNA = [no. of Est. Targets/4.59 (µl/panel)] * [10 (µl reaction volume)/1 (µl DNA)]/10 ng (DNA/µl) * dilution factor.

Genotyping assays

Genomic DNA was extracted from cell lines or from tumor xenografts using the Pure Link genomic DNA Kit (Invitrogen). Three TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) were custom designed to detect specific EGFR mutations: del476/750, T790M, and C797S (see a list of primers and probes in Appendix Table S4). Reactions were carried out in the StepOnePlus real-time PCR system, using 10 ng of DNA per sample. Cycling conditions were as follows: 60°C for 30 s (one cycle), 95°C for 10 min (one cycle), 40 cycles at 94°C for 15 s, and 60°C for 1 min, followed by 30 s at 60°C. As a negative control, we used a sample without template (NTC). All samples were run in duplicates, and experiments were repeated three times.

In vitro monitoring cytotoxicity using the real-time cell analyzer (RTCA)

ADCC activity was examined using RTCA. H1975 cells were pretreated for 8 days with saline, CTX, 3×mAbs (20 µg/ml), or for 3 days with osimertinib (0.0025 µM). Thereafter, cells were transferred to RTCA’s E-plates (8,000 cells per well) and monitored overnight. Before adding NK cells, the previously indicated treatments were refreshed. NK92 cells were added in a volume of 100 µl per well. Treatment with 1% Triton X-100 was used as an indicator of maximal elimination of target cells.

Tumorigenic cell growth in mice

All animal studies were approved by the Weizmann Institute’s Review Board (IRB). CD1-nu/nu or NSG mice (8–9 weeks old females) were randomized into groups of 6–10 mice. Mice were injected subcutaneously in the right flank with cancer cells (3 × 10^5 or 4 × 10^5 per mouse). mAbs were injected intraperitoneally at 200 µg per mouse per injection, once every 3 days. Daily administration of TKIs used oral gavage. Tumor width (W) and length (L) were measured once a week with a caliper, and tumor volume (V) was calculated according to the following formula: V = 3.14 × (W^2 × L)/6. Body weight was evaluated once per week. Mice were euthanized when tumor size reached 1,500 mm^3. Body composition analysis was performed using the Minispec LF50 Body Composition Analyzer (from Bruker). We assessed lean tissue, fat, and fluids in live mice. Investigators were not blinded to the group allocation during the experiment and when assessing outcome.

Statistical and data analyses

Cell sorting data were analyzed using the FlowJo v10.0.7 software (Tree Star, Inc., Ashland, OR, USA). Staining intensity was determined using ImageJ. All data were analyzed using the Prism GraphPad software, and statistical analyses were performed using one or two-way ANOVA with Tukey or Bonferroni’s test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001). For the analysis of real-time PCR data, we applied two-tailed t-test (*P ≤ 0.05; **P ≤ 0.01). For exact P-values and additional statistical information, see Appendix Table S5.

Expanded View for this article is available online.

Acknowledgements

We thank Michael Sela for continuous help and Alon Harmelin, Inbal Biton, Nava Nevo, Ori Brenner, and Naama Feldman for guiding our animal studies.
Our laboratory was supported by the European Research Council, the Israel Science Foundation, the Seventh Framework Program of the European Commission (LungTarget Consortium), the Israel Cancer Research Fund and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. Y.Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. Our studies were performed in the Marvin Tanner Laboratory for Research on Cancer.

Author contributions
MM and YY designed the study; MM, HG, NG, LM, DR, TMS, ML, GM, YE, DGAB, LR, AN, IM, and REA performed the experiments; MM, VK, DA, and YY analyzed data; EB, JD, and AM provided reagents; MM, VK, and YY wrote the manuscript. All authors declare no competing interests. Requests for reagents should be addressed to YY.

Conflict of interest
Yeda, the technology transfer office of the Weizmann Institute, protected relevant intellectual property. All authors declare that they have no other conflict of interests.

References


License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.